Skip to main content

Table 1 Baseline Characteristics of the Study Population

From: Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

Study Population Characteristics

All Participants (n = 300)

Age, mean, years (SD)

45.9 (13.1)

Women, n (%)

257 (85.7%)

Number of Monthly Headache Days, mean, days (SD)

23 (4.9)

Number of Monthly Migraine Days, mean, days (SD)

16.8 (6.4)

Number of Prior Failed Preventive Medications, median (IQR)

7 (5 – 9)

Number of Patients using Concomitant Preventive Medication at Baseline, n (%)

89 (29.7%)

  1. All patients were diagnosed with chronic migraine without medication overuse headache. Abbreviations: SD standard deviation, IQR interquartile range